文献速递心境障碍

辅助强光疗法治疗双相抑郁:随机双盲安慰剂对照试验

Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial.
PubMed 文献 · Am J Psychiatry · 2017-10-03

该研究纳入正在服用稳定抗躁狂药物的双相I或II型抑郁成人,随机接受7000勒克斯强白光或50勒克斯暗红光安慰剂治疗6周。结果显示强光组在第4-6周缓解率显著更高(68.2% vs 22.2%),终点抑郁评分显著更低,未观察到心境极性转换,两组睡眠质量改善无显著差异。

要点

  • 午间7000勒克斯强光辅助治疗双相抑郁可显著提高缓解率并降低抑郁评分。
  • 研究期间未观察到心境极性转换,提示短期使用未见躁狂/轻躁狂风险信号。
  • 两组睡眠质量均改善且无显著组间差异,强光对睡眠的额外获益不明确。

核心结论

  • 午间强光疗法对双相抑郁具有辅助疗效,可提高缓解率并降低抑郁症状水平。

研究设计与样本

  • 6周随机双盲安慰剂对照试验,纳入服用稳定剂量抗躁狂药物的双相I或II型抑郁成人,强光组与安慰剂组各23例。

主要发现

  • 第4-6周强光组缓解率68.2%,安慰剂组22.2%,调整比值比=12.6。
  • 终点访视强光组抑郁评分9.2(SD=6.6),安慰剂组14.9(SD=9.2),调整β=-5.91。
  • 未观察到心境极性转换,两组睡眠质量均改善且无显著组间差异。

关键数值与推荐

  • 缓解定义为SIGH-ADS评分≤8。
  • 强光治疗参数为7000勒克斯亮白光,安慰剂为50勒克斯暗红光。

临床怎么用

  • 对于正在服用稳定抗躁狂药物且无混合症状或快速循环的双相抑郁成人,可考虑午间强光疗法作为辅助治疗。

局限性

  • 每组样本量较小(N=23),研究周期为6周,长期疗效与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited treatment options. Building on promising pilot data, the authors conducted a 6-week randomized double-blind placebo-controlled trial to investigate the efficacy of adjunctive bright light therapy at midday for bipolar depression. The aims were to determine remission rate, depression symptom level, and rate of mood polarity switch, as well as to explore sleep quality. METHOD: The study enrolled depressed adults with bipolar I or II disorder who were receiving stable dosages of antimanic medication (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling). Patients were randomly assigned to treatment with either 7,000-lux bright white light or 50-lux dim red placebo light (N=23 for each group). Symptoms were assessed weekly with the Structured Interview Guide for the Hamilton Depression Scale With Atypical Depression Supplement (SIGH-ADS), the Mania Rating Scale, and the Pittsburgh Sleep Quality Index. Remission was defined as having a SIGH-ADS score of 8 or less. RESULTS: At baseline, both groups had moderate depression and no hypomanic or manic symptoms. Compared with the placebo light group, the group treated with bright white light experienced a significantly higher remission rate (68.2% compared with 22.2%; adjusted odds ratio=12.6) at weeks 4-6 and significantly lower depression scores (9.2 [SD=6.6] compared with 14.9 [SD=9.2]; adjusted β=-5.91) at the endpoint visit. No mood polarity switches were observed. Sleep quality improved in both groups and did not differ significantly between them. CONCLUSIONS: The data from this study provide robust evidence that supports the efficacy of midday bright light therapy for bipolar depression.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sit DK, McGowan J, Wiltrout C, et al. Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2017. PMID: 28969438. doi:10.1176/appi.ajp.2017.16101200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。